Diagnostic and Therapeutic Mechanisms of Depression Based on CRISPR Gene Editing and Brain-Machine Interface Technologies
DOI:
https://doi.org/10.61173/xqe5h306Keywords:
Depression, CRISPR, BCIAbstract
Depression, particularly treatment-resistant depression (TRD), is characterized by symptoms such as depressed mood, motivation lack, and recurrent relapses. It significantly impacts the normal work and daily life of patients. In the long run, the absence of effective treatment is one of most crucial factors leading to disability among these patients. Traditional therapies such as pharmacotherapy and psychotherapy are ineffective in a substantial number of patients. Therefore, there is an urgent imperative to develop revolutionary diagnostic and therapeutic strategies. This study delves into therapeutic strategies and clinical challenges of treatment of two new technologies for TRD. CRISPR technology identified potential targets and performed target editing of depression related genes such as FZD6, BDNF, LRFN5 and OTX2. Such editing contributes to regulating neural plasticity at the genetic level. BCI technology summarized and analyzed two distinct algorithms that decoded electroencephalogram (EEG) signals to offer objective biomarkers for diagnosis. Additionally, it discussed the use of closed - loop systems to modulate neuromodulation techniques such as deep brain stimulation (DBS) in real time for personalized treatment. This study indicates that both offer highly valuable breakthrough directions for addressing TRD despite the different technical pathways of the two approaches with one focusing on the genetic level and the other on the neural circuit level. These findings contribute to develop diagnostic and therapeutic strategies for TRD.
References
[1] Mokdad A H, Bisignano C, Hsu J M, et al. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021. The Lancet, 2024, 404(10469): 2341-2370.Amjady N. S.
[2] Tian W, Yan G, Xiong S, et al. Burden of depressive and anxiety disorders in China and its provinces, 1990–2021: findings from the global burden of disease study 2021. The British Journal of Psychiatry, 2025: 1-11.
[3] Xu Jingwen, Zhao Jingting, Wang Minzhe, Tian Qi, Li Xinyun. Comprehensive Analysis of the Incidence and Prognosis Trends of Depression in China: A Multi-Dimensional Study Based on the CHARLS, CLHLS and CHNS Databases. Clinical Personalized Medicine, 2025, 4(2): 715-719.
[4] World Health Organization. Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression. 2023.
[5] Ge Jile, Yu Dongsheng. Research Progress on Treatment Methods for Refractory Depression [J]. Clinical Medicine Progress, 2023, 13(3): 3860-3865.
[6] Chinese Medical Association. Guidelines for the Prevention and Treatment of Depression in China. Chinese Medical Multimedia Press, 2015.
[7] Han H, Xu M, Wang J, et al. CRISPR/Cas9 based gene editing of Frizzled class receptor 6 (FZD6) reveals its role in depressive symptoms through disrupting Wnt/β-catenin signaling pathway[J]. Journal of Advanced Research, 2024, 58: 129-138.
[8] Khadidos A O, Alyoubi K H, Mahato S, et al. Computer aided detection of major depressive disorder (MDD) using electroencephalogram signals. IEEE Access, 2023, 11: 41133- 41141.
[9] Thoduparambil P P, Dominic A, Varghese S M. EEG-based deep learning model for the automatic detection of clinical depression. Physical and Engineering Sciences in Medicine, 2020, 43(4): 1349-1360.
[10] Bergfeld I O, Mantione M, Hoogendoorn M L C, et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA psychiatry, 2016, 73(5): 456-464.
[11] Dougherty D D, Rezai A R, Carpenter L L, et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment- Dean&Francis ISSN 2959-409X resistant depression. Biological psychiatry, 2015, 78(4): 240- 248.
[12] Scangos K W, Khambhati A N, Daly P M, et al. Closedloop neuromodulation in an individual with treatment-resistant depression. Nature medicine, 2021, 27(10): 1696-1700.
[13] Scangos K W, Makhoul G S, Sugrue L P, et al. Statedependent responses to intracranial brain stimulation in a patient with depression. Nature medicine, 2021, 27(2): 229-231.
[14] Shanechi M M. Brain–machine interfaces from motor to mood. Nature neuroscience, 2019, 22(10): 1554-1564.
[15] Zhang C, Zhang Y, Luo H, et al. Bilateral Habenula deep brain stimulation for treatment-resistant depression: clinical findings and electrophysiological features. Translational psychiatry, 2022, 12(1): 52.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
